The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡

Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021 · cited 1×

A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C

Wai, C.-T., Greenson, J. K., Fontana, R. J., Kalbfleisch, J. D., Marrero, J. A., Conjeevaram, H. S., & Lok, A. S.-F. (2003) · Hepatology · doi:10.1053/jhep.2003.50346 · Cited by 4,406

The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

Chalasani, N., Younossi, Z. M., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. J., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,854

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987

Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies

D'Amico, G., Garcia-Tsao, G., & Pagliaro, L. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.10.013 · Cited by 2,687

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease

Estes, C., Razavi, H. A., Loomba, R. S., Younossi, Z. M., & Sanyal, A. J. (2017) · Hepatology · doi:10.1002/hep.29466 · Cited by 2,496

Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up

Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis

Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965

Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis

García–Tsao, G., Sanyal, A. J., Grace, N. D., & Carey, W. (2007) · Hepatology · doi:10.1002/hep.21907 · Cited by 1,714

Integrating liver endpoints in clinical trials of cardiovascular and kidney disease

Zannad, F. M., Sanyal, A. J., Butler, J., Miller, V., & Harrison, S. A. (2024) · Nature Medicine · doi:10.1038/s41591-024-03223-z · Cited by 46

Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis

Treem, W. R., Palmer, M., Lonjon‐Domanec, I., Seekins, D. W., Dimick‐Santos, L., Avigan, M., MARCINAK, J. F., Dash, A., Regev, A., Maller, E. S., et al. (2020) · Drug Safety · doi:10.1007/s40264-020-01014-2 · Cited by 43

The Hepatic Sinusoid in Chronic Liver Disease: The Optimal Milieu for Cancer

Gibert‐Ramos, A., Sanfeliu-Redondo, D., Aristu-Zabalza, P., Martínez-Alcocer, A., Gracia‐Sancho, J., Guixé‐Muntet, S., & Fernández‐Iglesias, A. (2021) · Cancers · doi:10.3390/cancers13225719 · Cited by 44

The Role of Gut Microbiota-Bile Acids Axis in the Progression of Non-alcoholic Fatty Liver Disease

Ni, Y., Lu, M., Xu, Y., Wang, Q., Gu, X., Li, Y., Zhuang, T., Xia, C., Zhang, T., Gou, X., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.908011 · Cited by 45

NIS2+TM as a screening tool to optimize patient selection in metabolic dysfunction-associated steatohepatitis clinical trials

Ratziu, V., Harrison, S. A., Hajji, Y., Magnanensi, J., Petit, S., Majd, Z., Delecroix, E., Rosenquist, C., Hum, D. W., Staels, B., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.10.038 · Cited by 39

Hepatic immune regulation and sex disparities

Burra, P., Zanetto, A., Schnabl, B., Reiberger, T., Montaño‐Loza, A. J., Asselta, R., Karlsen, T. H., & Tacke, F. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00974-5 · Cited by 43

Non-invasive tools for compensated advanced chronic liver disease and portal hypertension after Baveno VII – an update

Segna, D., Mendoza, Y. P., Lange, N. F., Rodrigues, S. G., & Berzigotti, A. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2022.10.009 · Cited by 38

Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients With Diabetes Mellitus: New Insights From CANVAS

Borisov, A. N., Kutz, A., Christ, E., Heim, M. H., & Ebrahimi, F. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad249 · Cited by 37

From “Burnt-Out” to “Burning-Out”: Capturing Liver Fat Loss in Patients With Advanced Metabolic Dysfunction–Associated Steatotic Liver Disease From a Dynamic Perspective

Liu, W., Huang, S., Ji, H., Kim, S. U., Yip, T. C., Wong, G. L., Petta, S., Tsochatzis, E. A., Nakajima, A., Bugianesi, E., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.02.034 · Cited by 38

Non-alcoholic Fatty Liver Disease and Diabetes Mellitus

Khneizer, G. W., Rizvi, S., & Gawrieh, S. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_532 · Cited by 41

Prognostic utility of magnetic resonance elastography and MEFIB index in predicting liver-related outcomes and mortality in individuals at risk of and with nonalcoholic fatty liver disease

Ajmera, V. H., Nguyen, K., Tamaki, N., Sharpton, S. R., Bettencourt, R., & Loomba, R. S. (2022) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848221093869 · Cited by 37

Unpaired virtual histological staining using prior-guided generative adversarial networks

Yan, R., He, Q., Liu, Y., Ye, P., Zhu, L., Shi, S., Gou, J., He, Y., Guan, T., & Zhou, G. (2023) · Computerized Medical Imaging and Graphics · doi:10.1016/j.compmedimag.2023.102185 · Cited by 36

Enhanced liver Fibrosis® test predicts liver-related outcomes in the general population

Saarinen, K., Färkkilä, M. A., Jula, A., Erlund, I., Vihervaara, T., Lundqvist, A., & Åberg, F. O. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100765 · Cited by 37

Validation of AGA clinical care pathway and AASLD practice guidance for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes

Ajmera, V. H., Tesfai, K., Sandoval, E., Lopez, S. J., Cervantes, V., Madamba, E. V., Bettencourt, R., Manousou, P., Richards, L., & Loomba, R. S. (2023) · Hepatology · doi:10.1097/hep.0000000000000635 · Cited by 36

Preliminary fatty liver disease grading using general-purpose online large language models: ChatGPT-4 or Bard?

Zhang, Y., Liu, H., Sheng, B., Tham, Y. C., & Ji, H. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.11.017 · Cited by 35

A PDCD1 Role in the Genetic Predisposition to NAFLD-HCC?

Eldafashi, N., Darlay, R., Shukla, R., McCain, M. V., Watson, R., Liu, Y. L., McStraw, N. M., Fathy, M., Fawzy, M. A., Zaki, M. Y. W., et al. (2021) · Cancers · doi:10.3390/cancers13061412 · Cited by 37

PRO‐C3 and ADAPT algorithm accurately identify patients with advanced fibrosis due to alcohol‐related liver disease

Madsen, B. S., Thiele, M. S., Detlefsen, S., Kjærgaard, M., Møller, L. S., Trebicka, J., Nielsen, M. J., Gudmann, N. S., Leeming, D. J., Karsdal, M. A., et al. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16513 · Cited by 35

Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)

Marchesini, G., Bugianesi, E., Burra, P., Marra, F., Miele, L., Alisi, A., Vajro, P., Masarone, M., Petta, S., Persico, M., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.04.028 · Cited by 70

Lysyl oxidase like-2 in fibrosis and cardiovascular disease

Poe, A., Yus, M. M., Wang, H., & Santhanam, L. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00176.2023 · Cited by 37

A roadmap for clinical trials in MASH-related compensated cirrhosis

Pericàs, J. M., Anstee, Q. M., Augustín, S., Bataller, R. A., Berzigotti, A., Ciudin, A., Francque, S., Abraldeṣ, J. G., Hernández–Gea, V., Pons, M., et al. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00955-8 · Cited by 38

Prediction of advanced fibrosis in non-alcoholic fatty liver disease using gut microbiota-based approaches compared with simple non-invasive tools

Lang, S., Farowski, F., Martin, A., Wisplinghoff, H., Vehreschild, M. J. G. T., Krawczyk, M. J., Nowag, A., Kretzschmar, A., Scholz, C. J., Kasper, P., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-66241-0 · Cited by 35

Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis

Younossi, Z. M., Stepanova, M., Noureddin, M., Kowdley, K. V., Strasser, S. I., Kohli, A., Ruane, P. J., Shiffman, M. L., Sheikh, A. M., Gunn, N., et al. (2021) · Hepatology Communications · doi:10.1002/hep4.1710 · Cited by 35

Endpoints in NASH Clinical Trials: Are We Blind in One Eye?

Lonardo, A., Ballestri, S., Mantovani, A., Targher, G., & Bril, F. (2024) · Metabolites · doi:10.3390/metabo14010040 · Cited by 34

Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease

Josloff, K., Beiriger, J., Khan, A., Gawel, R. J., Kirby, R. S., Kendrick, A. D., Rao, A. K., Wang, R. X., Schafer, M., Pearce, M. E., et al. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9120419 · Cited by 35

Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso)

Moreira, R. O., Valério, C. M., Villela‐Nogueira, C. A., Cercato, C., Gerchman, F., Lottenberg, A. M., Godoy‐Matos, A. F., Oliveira, R. D. A., Brandão‐Mello, C. E., Álvares‐da‐Silva, M. R., et al. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2023-0123 · Cited by 45

MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials

Zannad, F. M., Sanyal, A. J., Butler, J., Ferreira, J. P., Girerd, N., Miller, V., Pandey, A., Parikh, C. R., Ratziu, V., Younossi, Z. M., et al. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13793 · Cited by 38

Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)

Marchesini, G., Bugianesi, E., Burra, P., Marra, F., Miele, L., Alisi, A., Vajro, P., Masarone, M., Petta, S., Persico, M., et al. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.04.029 · Cited by 34

MRI-AST (MAST) Score Accurately Predicts Major Adverse Liver Outcome, Hepatocellular Carcinoma, Liver Transplant, and Liver-Related Death

Truong, E., GORNBEIN, J. A., Yang, J. D., Noureddin, N., Harrison, S. A., Alkhouri, N., & Noureddin, M. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.02.003 · Cited by 33

Noninvasive liver disease assessment to identify portal hypertension: Systematic and narrative reviews supporting the AASLD Practice Guideline

Rockey, D. C., Alsawas, M., Duarte‐Rojo, A., Patel, K., Levine, D., Asrani, S. K., Hasan, B., Nayfeh, T., Alsawaf, Y., Saadi, S. M., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000841 · Cited by 36

Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Wang, Y., Song, S. J., Jiang, Y., Lai, J. C., Wong, G. L., Wong, V. W., & Yip, T. C. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0246 · Cited by 32

The Role of Hepatic Venous Pressure Gradient in the Management of Cirrhosis

van Zanten, D. V., Buganza‐Torio, E., & Abraldeṣ, J. G. (2021) · Clinics in Liver Disease · doi:10.1016/j.cld.2021.01.002 · Cited by 33

Hepatic Outcomes of Nonalcoholic Fatty Liver Disease Including Cirrhosis and Hepatocellular Carcinoma

Alqahtani, S. A., Chan, W., & Yu, M. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.019 · Cited by 32

Changing trends of liver transplantation and mortality from non-alcoholic fatty liver disease

Majumdar, A., & Tsochatzis, E. A. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154291 · Cited by 32

Portal hypertension in primary biliary cholangitis: prevalence, natural history and histological correlates

Warnes, T. W., Roberts, S. A., Smith, A., Cope, V. M., Vales, P., Haboubi, N. Y., & McMahon, R. F. (2020) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002033 · Cited by 33

A practical use of noninvasive tests in clinical practice to identify high‐risk patients with nonalcoholic steatohepatitis

Younossi, Z. M., Alkhouri, N., Cusi, K., Isaacs, S. D., Kanwal, F., Noureddin, M., Loomba, R. S., Ravendhran, N., Lam, B. P., Nader, K., et al. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17346 · Cited by 31

Current challenges and future perspectives in treating patients with NAFLD-related cirrhosis

Mallet, M., Silaghi, C. A., Sultanik, P., Conti, F., Rudler, M., Ratziu, V., Thabut, D., & Pais, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000456 · Cited by 31

Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: Analysis of a French national hospital database

Boursier, J., Shreay, S., Fabron, C., Torreton, E., & Fraysse, J. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100445 · Cited by 30

The Natural History of NAFLD, a Community-Based Study at a Large Health Care Delivery System in the United States

Nyberg, L. M., Cheetham, C. T., Patton, H. M., Yang, S.-J., Chiang, K. M., Caparosa, S. L., Stern, J. A., & Nyberg, A. H. (2020) · Hepatology Communications · doi:10.1002/hep4.1625 · Cited by 30

Updated S2k clinical practice guideline on non-alcoholic fatty liver disease (NAFLD) issued by the German society of gastroenterology, digestive and metabolic diseases (DGVS)–April 2022–AWMF Registration No.: 021–025

Authors, & Collaborators: (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2388 · Cited by 30

Portal hypertension in patients with nonalcoholic fatty liver disease: Current knowledge and challenges

Madir, A., Grgurević, I., Tsochatzis, E. A., & Pinzani, M. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i4.290 · Cited by 32

The Placebo Response in Randomized Trials in Nonalcoholic Steatohepatitis Simply Explained

Rowe, I. A. C., & Parker, R. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.05.059 · Cited by 28

Fibrosis progression rate in a systematic review of placebo‐treated nonalcoholic steatohepatitis

Roskilly, A., Hicks, A., Taylor, E., Jones, R. L., Parker, R., & Rowe, I. A. C. (2020) · Liver International · doi:10.1111/liv.14749 · Cited by 27

Age, Gender and Geographic Differences in Global Health Burden of Cirrhosis and Liver Cancer due to Nonalcoholic Steatohepatitis

Zhang, T., Xu, J., Ye, L., Lin, X., Xu, Y., Pan, X., Weng, X., Ye, C., Fan, L., Ren, Y., et al. (2021) · Journal of Cancer · doi:10.7150/jca.52282 · Cited by 27

Diagnostic accuracy of enhanced liver fibrosis test for nonalcoholic steatohepatitis‐related fibrosis: Multicenter study

Seko, Y., Takahashi, H., Toyoda, H., Hayashi, H., Yamaguchi, K., Iwaki, M., Yoneda, M., Arai, T., Shima, T., Fujii, H., et al. (2022) · Hepatology Research · doi:10.1111/hepr.13871 · Cited by 27

Noninvasive assessment of hepatic decompensation

Thiele, M. S., Johansen, S., Israelsen, M. E., Trebicka, J., Abraldeṣ, J. G., Ginès, P., & Krag, A. A. (2023) · Hepatology · doi:10.1097/hep.0000000000000618 · Cited by 27

New Drugs for NASH and HIV Infection: Great Expectations for a Great Need

Guaraldi, G., Maurice, J. B., Marzolini, C., Monteith, K. M., Milić, J., Tsochatzis, E. A., Bhagani, S. R., Morse, C. G., Price, J. C., Ingiliz, P., et al. (2020) · Hepatology · doi:10.1002/hep.31177 · Cited by 26

Safety and Efficacy of Bariatric Surgery in Cirrhosis Patients With Extreme Obesity

Vuppalanchi, R., McCabe, M. E., Tandra, S., Parcha, S. P., Ghafoor, A., Schuh, L., Inman, M. M., Selzer, D. J., Stefanidis, D., & Chalasani, N. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000003891 · Cited by 26

A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH

Harrison, S. A., Alkhouri, N., Ortiz‐Lasanta, G., Rudraraju, M., Tai, D., Wack, K., Shah, A., Besuyen, R., Steineger, H. H., Fraser, D. A., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.01.032 · Cited by 28

Noninvasive Markers of Portal Hypertension Detect Decompensation in Overweight or Obese Patients With Compensated Advanced Chronic Liver Disease

Mendoza, Y. P., Cocciolillo, S., Murgia, G., Chen, T., Margini, C., Sebastiani, G., & Berzigotti, A. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.04.018 · Cited by 25

Relationship of ELF and PIIINP With Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial

Gawrieh, S., Wilson, L., Yates, K. P., Cummings, O. W., Vilar‐Gómez, E., Ajmera, V. H., Kowdley, K. V., Rosenberg, W. M., Tonascia, J., & Chalasani, N. (2021) · Hepatology Communications · doi:10.1002/hep4.1680 · Cited by 25

New Rat Model of Advanced NASH Mimicking Pathophysiological Features and Transcriptomic Signature of The Human Disease

Maeso‐Díaz, R., Boyer‐Díaz, Z., Lozano, J. J., Ortega‐Ribera, M., Peralta, C., Bosch, J., & Gracia‐Sancho, J. (2019) · Cells · doi:10.3390/cells8091062 · Cited by 26

MEFIB‐Index and MAST‐Score in the assessment of hepatic decompensation in metabolic dysfunction‐associated steatosis liver disease—Individual participant data meta‐analyses

Noureddin, N., Ajmera, V. H., Bergstrom, J., Bettencourt, R., Huang, D. Q., Siddiqi, H., Majzoub, A. M., Nayfeh, T., Tamaki, N., Izumi, N., et al. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17707 · Cited by 24

Monitoring disease progression in metabolic dysfunction‐associated steatotic liver disease

Noureddin, N., Copur‐Dahi, N., & Loomba, R. S. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17752 · Cited by 25

Metabolic Dysfunction-Associated Steatotic Liver Disease: A Silent Driver of Cardiovascular Risk and a New Target for Intervention

Gallo, G., Nalli, G., Baratta, F., Desideri, G., & Savoia, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26168081 · Cited by 27

Squalene Epoxidase: Its Regulations and Links with Cancers

Zhang, L., Cao, Z., Hong, Y., He, H. H., Chen, L., Yu, Z., & Gao, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073874 · Cited by 22

Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications

Hydes, T., Brown, E. E., Hamid, A., Bateman, A. C., & Cuthbertson, D. J. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.07.012 · Cited by 22

Birth Weight, Gestational Age, and Risk of Pediatric-Onset MASLD

Ebrahimi, F., Yao, J., Hagström, H., Stephansson, O., Sun, J., Bergman, D., Söderling, J. K., & Ludvigsson, J. F. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.32420 · Cited by 21

The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices

Paternostro, R., Becker, J., Hofer, B. S., Panagl, V., Schiffke, H., Simbrunner, B., Semmler, G., Schwabl, P., Scheiner, B., Bucsics, T., et al. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.09.009 · Cited by 17

Cytoskeleton alterations in non-alcoholic fatty liver disease

Pessoa, J., & Teixeira, J. (2021) · Metabolism · doi:10.1016/j.metabol.2021.155115 · Cited by 21

The emerging significance of mitochondrial targeted strategies in NAFLD treatment

Zhang, T., Nie, Y., & Wang, J. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121943 · Cited by 21

Metabolic dysfunction-associated steatotic liver disease heterogeneity: Need of subtyping

Habib, S. (2024) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v15.i2.92791 · Cited by 21

Helicobacter pylori infection and nonalcoholic fatty liver disease: Are the four meta-analyses favoring an intriguing association pointing to the right direction?

Pοlyzos, S. A., Kountouras, J., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.05.006 · Cited by 21

Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)

Associazione Italiana per lo Studio del Fegato (AISF), S. I. D. D. (. A. S. I. D. (. (2021) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-021-01287-1 · Cited by 22

MASLD , At‐Risk MASH and Increased Liver Stiffness Are Associated With Young Adulthood Obesity Without Residual Risk After Losing Obesity

van Kleef, L. A., Pustjens, J., Savas, M., Ayada, I., Li, P., Pan, Q., van Rossum, E. F. C., Janssen, H. L. A., & Brouwer, W. P. (2024) · Liver International · doi:10.1111/liv.16169 · Cited by 20

Estimates and trends of the global burden of NASH-related liver cancer attributable to high fasting plasma glucose in 1990–2019: analysis of data from the 2019 Global Burden of Disease Study

Li, Z., Yang, N., He, L., Wang, J., Ping, F., Li, W., Xu, L., Zhang, H., & Li, Y. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00976-w · Cited by 20

Pharmacotherapies of NAFLD: updated opportunities based on metabolic intervention

Shao, Y., Chen, S., Liu, H., & Liu, J. (2023) · Nutrition & Metabolism · doi:10.1186/s12986-023-00748-x · Cited by 20

Dual Role of Pregnane X Receptor in Nonalcoholic Fatty Liver Disease

Xu, Y., An, Z., Wang, S., Ni, Y., Zhou, M., Feng, Q., Gou, X., Xu, M., & Qi, Y. (2023) · Current Molecular Pharmacology · doi:10.2174/0118761429259143230927110556 · Cited by 19

Value-Based Pricing of Resmetirom for Metabolic Dysfunction–Associated Steatotic Liver Disease

Le, P., Dasarathy, S., Herman, W. H., Adekunle, O. A., Tran, H. T., Criswell, V., Ye, W., Welch, N., Yue, Y., & Rothberg, M. B. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.17122 · Cited by 20

Screening for advanced steatotic liver disease

Johansen, S., Åberg, F. O., Tsochatzis, E. A., & Krag, A. A. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00097-4 · Cited by 19

Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH)

Sebastiani, G., Patel, K., Ratziu, V., Feld, J. J., Neuschwander‐Tetri, B. A., Pinzani, M., Petta, S., Berzigotti, A., Metrakos, P. P., Shoukry, N. H., et al. (2021) · Canadian Liver Journal · doi:10.3138/canlivj-2021-0030 · Cited by 20

Transcatheter interventions for valvular heart diseases in liver cirrhosis patients

Ahmed, T., Misumida, N., Grigorian, A. Y., Tarantini, G., & Messerli, A. W. (2021) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.12.014 · Cited by 19

The use of current knowledge and non‐invasive testing modalities for predicting at‐risk non‐alcoholic steatohepatitis and assessing fibrosis

Kugelmas, M., Noureddin, M., Gunn, N., Brown, K., Younossi, Z. M., Abdelmalek, M. F., & Alkhouri, N. (2023) · Liver International · doi:10.1111/liv.15555 · Cited by 18

Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort

Sanyal, A. J., Muñoz, B., Cusi, K. J., Barritt, A. S., Muthiah, M. D., Mospan, A. R., Reddy, K. R., Firpi-Morell, R. J., Thuluvath, P. J., Bhamidimarri, K. R., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.02.024 · Cited by 19

Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 study

Sanyal, A. J., Loomba, R. S., Anstee, Q. M., Ratziu, V., Kowdley, K. V., Rinella, M. E., Harrison, S. A., Resnick, M. B., Capozza, T. A., Sawhney, S., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000325 · Cited by 19

Understanding MASH: An Examination of Progression and Clinical Outcomes by Disease Severity in the TARGET-NASH Database

Luthra, R., & Sheth, A. (2024) · Advances in Therapy · doi:10.1007/s12325-024-03085-4 · Cited by 21

Endovascular Assessment of Liver Hemodynamics in Patients with Cirrhosis Complicated by Portal Hypertension

Ferral, H., Schepis, F., Gaba, R. C., García–Tsao, G., Zanetto, A., Pérez‐Campuzano, V., Haskal, Z. J., & García‐Pagán, J. C. (2022) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2022.12.014 · Cited by 18

State of CD8+ T cells in progression from nonalcoholic steatohepatitis to hepatocellular carcinoma: From pathogenesis to immunotherapy

Zhong, X., Lv, M., Ma, M., Huang, Q., Hu, R., Li, J., Yi, J., Sun, J., & Zhou, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115131 · Cited by 20

Relationship of Enhanced Liver Fibrosis Score with Pediatric Nonalcoholic Fatty Liver Disease Histology and Response to Vitamin E or Metformin

Gawrieh, S., Adams, K. H., Pike, F., Yates, K. P., Wilson, L., Cummings, O. W., Rosenberg, W. M., Chalasani, N., & Molleston, J. P. (2021) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2021.08.012 · Cited by 17

Portal Hypertension in Nonalcoholic Fatty Liver Disease: Challenges and Paradigms

Mitten, E. K., Portincasa, P., & Baffy, G. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2023.00029 · Cited by 17

Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies

Agyapong, G., Dashti, F., & Banini, B. A. (2023) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15012 · Cited by 18

mARC1 in MASLD: Modulation of lipid accumulation in human hepatocytes and adipocytes

Jones, A. K., Bajrami, B., Campbell, M. K., Erzurumluoglu, A. M., Guo, Q., Chen, H., Zhang, X., Zeveleva, S., Kvaskoff, D., Brunner, A., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000365 · Cited by 18

Serum autotaxin is a prognostic indicator of liver-related events in patients with non-alcoholic fatty liver disease

Iwadare, T., Kimura, T., Okumura, T., Wakabayashi, S., Nakajima, T., Kondo, S., Kobayashi, H., Yamashita, Y., Sugiura, A., Fujimori, N., et al. (2024) · Communications Medicine · doi:10.1038/s43856-024-00499-7 · Cited by 18

Fructose, Omega 3 Fatty Acids, and Vitamin E: Involvement in Pediatric Non-Alcoholic Fatty Liver Disease

Alberti, G., Gana, J. C., & Santos, J. L. (2020) · Nutrients · doi:10.3390/nu12113531 · Cited by 18

Portal hypertension in nonalcoholic fatty liver disease: Challenges and perspectives

Miao, L., Targher, G., Byrne, C. D., Valenti, L. V. C., Qi, X., & Zheng, M. (2022) · Portal hypertension & cirrhosis · doi:10.1002/poh2.8 · Cited by 16

NAFLD and NASH: The Metabolically Diseased Liver

Armandi, A., & Schattenberg, J. M. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_561 · Cited by 16

The Potential Role of Fatigue in Identifying Patients With NASH and Advanced Fibrosis Who Experience Disease Progression

Younossi, Z. M., Stepanova, M., Myers, R. P., Younossi, I. M., & Henry, L. L. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.04.023 · Cited by 15

TASL Practice Guidance on the Clinical Assessment and Management of Patients with Nonalcoholic Fatty Liver Disease

Yilmaz, Y. N. (2023) · Hepatology forum/Hepatology forum (Online) · doi:10.14744/hf.2023.2023.0011 · Cited by 15

NASH cirrhosis trials and major adverse liver outcomes: Big data needed

Noureddin, M., & Harrison, S. A. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.10.022 · Cited by 15

Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy

Amatya, R., Lee, D.-H., Min, K. A., & Shin, M. C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071963 · Cited by 13

A Pragmatic Management Approach for Metabolic Dysfunction-Associated Steatosis and Steatohepatitis

Shah, N., & Sanyal, A. J. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003215 · Cited by 15

Integrated Multichip Analysis Identifies Potential Key Genes in the Pathogenesis of Nonalcoholic Steatohepatitis

Ye, J., Lin, Y., Wáng, Q., Li, Y., Zhao, Y., Chen, L., Wu, Q. H., Xu, C., Zhou, C., Sun, Y., et al. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.601745 · Cited by 14

Potential Therapeutic Targets and Promising Agents for Combating NAFLD

Umemura, A., Kataoka, S., Okuda, K., Seko, Y., Yamaguchi, K., Moriguchi, M., Okanoue, T., & Itoh, Y. (2022) · Biomedicines · doi:10.3390/biomedicines10040901 · Cited by 15

Non‐invasive candidate protein signature predicts hepatic venous pressure gradient reduction in cirrhotic patients after sustained virologic response

Richards, S. M., Guo, F., Zou, H., Nigsch, F., Baiges, A., Pachori, A. S., Zhang, Y., Lens, S., Pitts, R., Finkel, N., et al. (2023) · Liver International · doi:10.1111/liv.15657 · Cited by 13

Update on Clinical Trials for Nonalcoholic Steatohepatitis.

Nathani, R. R., & Bansal, M. B. (2023) · PubMed Central · Cited by 13

Non-invasive biomarkers prognostic of decompensation events in NASH cirrhosis: a systematic literature review

Amoroso, M., Augustín, S., Moosmang, S., & Gashaw, I. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02448-2 · Cited by 15

Liver stiffness can predict decompensation and need for beta-blockers in compensated cirrhosis: a step beyond Baveno-VI criteria

Jindal, A., Sharma, S., Agarwal, S., Kumar, M., Saraya, A., & Sarin, S. K. (2022) · Hepatology International · doi:10.1007/s12072-021-10280-w · Cited by 13

Noninvasive Tests Used in Risk Stratification of Patients with Nonalcoholic Fatty Liver Disease

Henry, L. L., Eberly, K. E., Shah, D., Kumar, A. R., & Younossi, Z. M. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.022 · Cited by 13

Modifiers of Liver-Related Manifestation in the Course of NAFLD

Nasr, P., Blomdahl, J., Kechagias, S., & Ekstedt, M. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200310142803 · Cited by 13

AI-based histologic scoring enables automated and reproducible assessment of enrollment criteria and endpoints in NASH clinical trialsPreprint

Iyer, J. S., Pokkalla, H., Biddle-Snead, C., Carrasco‐Zevallos, O. M., Lin, M., Shanis, Z., Le, Q., Juyal, D., Pouryahya, M., Pedawi, A., et al. (2023) · medRxiv · doi:10.1101/2023.04.20.23288534 · Cited by 15

The future of hepatology

Friedman, S. L., & Sanyal, A. J. (2023) · Hepatology · doi:10.1097/hep.0000000000000389 · Cited by 12

Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis

Sanyal, A. J., Anstee, Q. M., Trauner, M., Lawitz, E. J., Abdelmalek, M. F., Ding, D., Han, L., Jia, C., Huss, R. S., Chung, C., et al. (2022) · Hepatology · doi:10.1002/hep.32204 · Cited by 171

The association of histologic and noninvasive tests with adverse clinical and patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis

Younossi, Z. M., Anstee, Q. M., Wai-Sun Wong, V., Trauner, M., Lawitz, E. J., Harrison, S. A., Camargo, M., Kersey, K., Subramanian, G. M., Myers, R. P., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.12.003 · Cited by 118

1876-P: Impact of Diabetes on Liver Disease Progression in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH)

Sanyal, A. J., Abdelmalek, M. F., Caldwell, S. H., Shiffman, M. L., Ghalib, R. H., Lawitz, E., Jiang, D., Schall, R. A., Mccolgan, B., Myers, R., et al. (2019) · Diabetes · doi:10.2337/db19-1876-p

The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH

Loomba, R. S., & Adams, L. A. (2019) · Hepatology · doi:10.1002/hep.30946 · Cited by 151

Changes in fibrosis, but not the NAFLD Activity Score (NAS), are associated with disease progression in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis

Sanyal, A. J., Harrison, S. A., Ratziu, V., Abdelmalek, M. F., Diehl, A. M., Caldwell, S. H., Shiffman, M. L., Aguilar, R., Jia, C., Mccolgan, B., et al. (2017) · Journal of Hepatology · doi:10.1016/s0168-8278(17)30267-2 · Cited by 10